People · Operator
Named in public records as an officer, director or promoter · active 2023–2025 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Claris Biotherapeutics, Inc. | — | Biotechnology | Series C | $60.1M | $13.0M | 2023 |
Henry Rath at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Henry Rath on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Meredith Fisher | 1 | 6 |
| Kenneth Harrison | 1 | 4 |
| Marc De Garidel | 1 | 3 |
| Reza Dana | 1 | 3 |
| Clarke Atwell | 1 | 2 |
| Susan Orr | 1 | 1 |
| Marc Clarke De Garidel | 1 | 1 |
| Anton Clarke Atwell | 1 | 1 |
| Meredith Clarke Fisher | 1 | 1 |
| Kenneth Clarke Harrison | 1 | 1 |
| Reza Clarke Dana | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.